首页|柴芩调肝胶囊辅助治疗乙型肝炎病毒感染患者的疗效分析

柴芩调肝胶囊辅助治疗乙型肝炎病毒感染患者的疗效分析

扫码查看
目的 探讨柴芩调肝胶囊治疗乙型肝炎病毒(HBV)感染患者的临床疗效.方法 2014年1月~2015年6月舟山医院治疗的126例HBV感染患者随机分成对照组和实验组:对照组63例,"干扰素+拉米夫定"治疗;实验组63例,"干扰素+拉米夫定+柴芩调肝胶囊"治疗.比较2组的HBsAg和HBV-DNA转阴、肝功能改善及不良反应发生情况.结果 对照组治疗3、6个月后的HBsAg转阴率和HBV-DNA转阴率均明显高于实验组(P<0.05);对照组、实验组治疗后的ALT、AST、直接胆红素(direct bilirubin,DBiL)水平明显下降,对照组治疗后的ALT、AST、DBiL水平明显低于实验组(P<0.05);对照组、实验组均未出现严重不良反应,组间比较无明显差异.结论 柴芩调肝胶囊可长疗程抑制乙肝病毒复制,改善肝功能,耐受性好且安全性高.
Curative effect of Chaiqin tiaogan capsule in treatment of patients with hepatitis B virus
Objective To investigate the clinical superiority of Chaiqin tiaogan capsule in the treatment of hepatitis B virus.Methods 126 cases of patients admitted to hospital from January 2014 to June 2015 were randomly divided into two groups, the control group (interferon and lamivudine) and the experimental group (interferon, lamivudine and Chaiqin tiaogan capsule), each group of 63 cases.The HBsAg and HBV-DNA negative rate, the changes of liver function and the incidence of adverse reactions in the experimental group were observed and compared.Results The HBsAg negative rate and the HBV-DNA negative rate after treatment three and six months in the control group were significantly higher than the experimental group ( P<0.05).The levels of ALT, AST and DBiL in the control group and the experimental group were significantly decreased, and the levels of ALT, AST and DBiL after treatment six months in the control group were significantly lower than the experimental group ( P <0.05 ) .There were no serious adverse reactions in the control group and experimental group, there was no significant difference between two groups.Conclusion Chaiqin tiaogan capsule can effectively inhibit HBV replication and improve liver function, it has good tolerability and safety applied to clinical.

HBVChaiqin tiaogan capsuleHBsAgHBV-DNAliver function

黎运呈、曾芳、郑迪、杨娟

展开 >

舟山医院 传染科,浙江 舟山 316021

舟山市妇幼保健院 产前诊断实验室,浙江舟山 316004

乙型肝炎病毒 柴芩调肝胶囊 乙肝表面抗原 乙肝病毒脱氧核糖核酸 肝功能

浙江省中医药科技计划浙江省卫生厅课题

2013ZQ0292013KYA211

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(2)
  • 1
  • 12